Published: 2015-07-01 08:01:32 CEST
Chr.Hansen Holding A/S
Quarterly report

Interim report Q3 (1 September - 31 May 2015)

Hoersholm, 2015-07-01 08:01 CEST --  

Company Announcement No. 9

The Interim Report for the first nine months of 2014/15 is hereby enclosed.

2014/15 YTD IN BRIEF

Solid organic revenue growth of 9% in the first nine months of 2014/15: Cultures & Enzymes Division 8%, Health & Nutrition Division 17% and Natural Colors Division 7%. EBIT before special items increased by 12% to EUR 160 million. Revenue measured in EUR increased by 13%, as Chr. Hansen was positively impacted by the appreciation of the USD.

EUR million Q3
2014/15
Q3
2013/14
Growth YTD
2014/15
YTD
2013/14
Growth
Revenue 228.1 198.1 15% 625.0 550.9 13%
EBIT* 63.8 55.0 16% 159.8 143.2 12%
Profit for the period 45.7 37.4 22% 111.0 93.7 18%
Free cash flow** 53.8 41.2 31% 65.0 46.5 40%
Organic growth 7% 10%   9% 7% 9%
Gross margin 52.4% 50.5%   51.4% 51.7%  
EBIT margin* 28.0% 27.8%   25.6% 26.0%  
ROIC excl. goodwill 39.0% 35.8%   33.8% 32.1%  

* Before special items.

**Before acquisitions, divestments and special items

“The performance in the first nine months of 2014/15 was encouraging with good progress across our divisions and strategic initiatives. Based on this we have narrowed our organic revenue expectations for 2014/15 to 8-9% (previously 7-9%). The EBIT margin is still expected to be above 26.5%, while free cash flow is now expected to be around EUR 150 million (previously above EUR 130 million)” says CEO Cees de Jong.

“Given the strong operational performance and free cash flow generation, we have decided to declare an interim dividend totaling EUR 115 million (DKK 6.57 per share) with a pay-out date of 9 July 2015.”

OUTLOOK FOR 2014/15

The outlook for 2014/15 has been adjusted compared to the announcements of 9 April 2015 and 22 October 2014.

                                                                                           1 July 2015                         9 April 2015

Organic revenue growth:                                              8-9%                                    7-9%

Research & development expenditures incurred

(% of revenue):                                                               around 7%                           7-8%

EBIT margin before special items:                             above 26.5%                       above 26.5%

Free cash flow before acquisitions, divestments

and special items around:                                            EUR 150 million                above EUR 130 million

 

For further information, please contact:

Anders Mohr Christensen, Senior Director, Investor Relations

Tel: +45 4574 7618

Klara Halkjaer, Head of Media Relations

Tel: +45 4574 7474

  

About Chr. Hansen

Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2013/14 financial year was EUR 756 million. The company holds a leading market position in all its divisions: Cultures & Enzymes, Health & Nutrition and Natural Colors. It has more than 2,500 dedicated employees in 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on Nasdaq Copenhagen. For further information, please visit www.chr-hansen.com.

 

 

 


Q3 2015 Interim Report..pdf